Gland Pharma

1,393.75
+0.95
(0.07%)
Market Cap
22,962.93 Cr
EPS
46.90
PE Ratio
32.59
Dividend Yield
1.44 %
Industry
Healthcare
52 Week High
2,220.95
52 Week Low
1,277.80
PB Ratio
2.61
Debt to Equity
0.02
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from10 analysts
SELL
Analysts have suggested that investors can sell this stock
Buy
Buy+40.00 %
+40.00 %
Hold
Hold+10.00 %
+10.00 %
Sell
Sell+50.00 %
+50.00 %
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,687.55
#1 4,04,899.77
33.61
#1 49,887.20
12.06
#1 9,648
13.77
47.60
5,589.30
1,48,378.35
69.15
8,184.00
0.89
1,600
#1 64.53
47.92
1,463.05
1,18,158.10
22.92
26,520.70
14.17
4,155
47.38
50.89
3,129.00
1,05,899.58
56.83
10,785.70
11.59
1,656
13.54
45.29
2,350.50
96,976.58
46.77
10,615.60
19.57
1,942
-16.38
48.68
1,109.50
92,582.82
#1 17.01
28,905.40
12.36
5,578
1.69
40.66
1,969.25
89,904.33
30.58
20,141.50
#1 19.94
1,936
38.82
46.62
868.85
87,426.64
18.74
19,831.50
13.82
3,831
29.92
44.56
29,641.10
62,985.27
46.40
6,097.20
10.80
1,201
16.01
48.36
1,082.45
62,868.87
17.41
29,559.20
17.55
3,169
-10.04
41.61
Growth Rate
Revenue Growth
50.97 %
Net Income Growth
-1.09 %
Cash Flow Change
173.87 %
ROE
-9.79 %
ROCE
-5.23 %
EBITDA Margin (Avg.)
-21.30 %

Quarterly Financial Results

Quarterly Financials
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
681
916
852
895
935
1,216
1,132
1,109
1,168
931
1,110
1,000
824
1,246
1,427
1,583
1,580
1,453
1,466
1,443
Expenses
395
472
534
595
560
718
704
714
755
587
748
649
673
915
1,049
1,189
1,179
1,137
1,109
1,024
EBITDA
286
445
318
299
375
498
428
395
414
344
363
351
151
332
377
394
401
316
357
418
Operating Profit %
38 %
47 %
36 %
31 %
37 %
38 %
35 %
33 %
32 %
32 %
28 %
31 %
14 %
24 %
24 %
23 %
23 %
19 %
21 %
26 %
Depreciation
24
24
25
25
25
25
26
28
31
35
37
38
38
65
81
105
93
92
94
96
Interest
1
1
1
1
1
1
1
1
2
1
2
3
2
5
6
5
10
6
6
23
Profit Before Tax
262
420
293
273
349
472
401
366
381
309
324
311
111
261
290
283
298
218
257
299
Tax
67
106
74
69
89
121
99
93
95
79
83
79
33
67
96
91
106
75
93
95
Net Profit
195
314
219
204
260
351
302
273
286
229
241
232
79
194
194
192
192
144
164
205
EPS in ₹
12.57
20.24
14.12
12.83
15.93
21.41
18.37
16.62
17.40
13.93
14.65
14.08
4.78
11.79
11.78
11.65
11.68
8.73
9.93
12.42

Balance Sheet

Balance Sheet
2020
2021
2022
2023
2024
Total Assets
4,086
6,496
7,834
8,778
10,661
Fixed Assets
968
954
1,502
1,571
3,947
Current Assets
2,846
5,124
5,852
6,901
5,645
Capital Work in Progress
189
338
191
177
238
Investments
0
0
155
0
0
Other Assets
2,930
5,204
5,986
7,030
6,477
Total Liabilities
4,086
6,496
7,834
8,778
10,661
Current Liabilities
359
513
582
729
1,398
Non Current Liabilities
81
80
94
90
539
Total Equity
3,646
5,903
7,158
7,959
8,724
Reserve & Surplus
3,631
5,887
7,141
7,942
8,707
Share Capital
16
16
16
17
17

Cash Flow

Cash Flow
2020
2021
2022
2023
2024
Net Cash Flow
-67
323
-174
1,590
-1,552
Investing Activities
-761
-1,520
-999
1,211
-1,749
Operating Activities
701
605
791
364
997
Financing Activities
-7
1,239
35
15
-799

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
58.25 %
58.14 %
58.02 %
58.00 %
58.00 %
57.87 %
57.86 %
57.86 %
57.86 %
57.86 %
57.86 %
57.86 %
57.86 %
51.83 %
51.83 %
51.83 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.01 %
0.01 %
0.00 %
4.91 %
0.00 %
3.59 %
6.88 %
4.47 %
5.04 %
DIIs
10.69 %
11.57 %
11.39 %
11.21 %
11.94 %
16.71 %
20.58 %
23.13 %
23.23 %
23.38 %
22.45 %
23.14 %
25.23 %
32.83 %
35.37 %
34.80 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
3.30 %
3.72 %
3.77 %
3.58 %
3.69 %
3.70 %
3.77 %
4.02 %
4.26 %
5.60 %
4.52 %
3.79 %
3.28 %
3.33 %
3.28 %
3.30 %
Others
27.76 %
26.58 %
26.81 %
27.21 %
26.37 %
21.71 %
17.78 %
14.98 %
14.64 %
13.16 %
10.27 %
15.22 %
10.04 %
5.12 %
5.04 %
5.04 %
No of Share Holders
84,467
98,203
1,09,326
1,09,097
1,09,098
1,17,339
1,27,879
1,48,469
1,50,578
1,81,747
1,61,627
1,36,021
1,22,375
1,22,665
1,22,358
1,21,075

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 20 0.00
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.26 0.00

Corporate Action

Announcements

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 20184 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 03, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 03, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 31, 2025
Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotMar 31, 2025
Closure of Trading WindowMar 28, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 24, 2025
ESOP Scheme 2025Mar 22, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 11, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 11, 2025
Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotMar 11, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 10, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMar 10, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMar 01, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 28, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 28, 2025
Approval Of Gland Pharma Employee Stock Option Scheme 2025 By Board Of DirectorsFeb 26, 2025
Approval Of Gland Pharma Employee Stock Option Scheme 2025 By Board Of DirectorsFeb 26, 2025
Board Meeting Outcome for Outcome Of Board Meeting - 26Th February 2025Feb 26, 2025
Board Meeting Outcome for Outcome Of Board Meeting - 26Th February 2025Feb 26, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSFeb 26, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSFeb 26, 2025
Conclusion Of US FDA Inspection At CompanyS JNPC Facility VisakhapatnamFeb 25, 2025
Conclusion Of US FDA Inspection At CompanyS JNPC Facility VisakhapatnamFeb 25, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 24, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 10, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 08, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 07, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 07, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 04, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 03, 2025
Integrated Filing (Financial)Feb 03, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 03, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 03, 2025
Board Meeting Outcome for Outcome Of Board Meeting For The Quarter Ended December 31 2024Feb 03, 2025
Unaudited Financial Results For The Quarter Ended December 31 2024Feb 03, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 30, 2025
Update On US FDA Inspection At Pashamylaram Facility HyderabadJan 18, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 16, 2025
Board Meeting Intimation for Unaudited Financial Results For The Quarter And Nine Months Ended 31.12.2024Jan 16, 2025
Update On USFDA Inspection At Dundigal FacilityJan 16, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJan 15, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 13, 2025
Closure of Trading WindowDec 27, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 13, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 11, 2024
Shareholder Meeting / Postal Ballot-Scrutinizers ReportDec 09, 2024
Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotDec 09, 2024
Announcement under Regulation 30 (LODR)-Change in ManagementDec 03, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 03, 2024

Technical Indicators

RSI(14)
Neutral
30.17
ATR(14)
Less Volatile
80.87
STOCH(9,6)
Neutral
21.31
STOCH RSI(14)
Oversold
2.25
MACD(12,26)
Bearish
-23.56
ADX(14)
Weak Trend
20.12
UO(9)
Bearish
33.45
ROC(12)
Downtrend And Accelerating
-13.44
WillR(14)
Neutral
-76.33

About Gland Pharma

Gland Pharma Limited is an Indian generic injectables manufacturer specializing in sterile injectables, oncology, and ophthalmic products. Founded in 1978, the company operates primarily on a B2B model, selling products in over 60 countries. It has 8 manufacturing facilities in India, including 4 for finished formulations and 3 for APIs. The company has 284 ANDA filings in the US, with 234 approved. It expanded its business to include contract development, dossier preparation, and technology transfer. In 2023, Gland Pharma acquired Cenexi through its Singapore subsidiary, adding 7 new subsidiaries. The company offers various delivery systems and key molecules such as Heparin Sodium and Enoxaparin Sodium Injections.
Listing Date
20 Nov, 2020(4 Years, 26 days)
Chairperson NameYiu Kwan Stanley Lau